{"id":59767,"date":"2024-07-29T04:04:47","date_gmt":"2024-07-29T02:04:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/"},"modified":"2024-07-29T04:04:47","modified_gmt":"2024-07-29T02:04:47","slug":"re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/","title":{"rendered":"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports"},"content":{"rendered":"
\n

PHILADELPHIA–(BUSINESS WIRE)–At the Alzheimer\u2019s Association International Conference (AAIC) from July 28th to August 1st, 2024 in Philadelphia\/USA, the results of the real-world application study re.cogni.ze were presented for the first time. The study, initiated by Roche and conducted in cooperation with the digital health company neotiv, examined the user-friendliness, adherence, and acceptance of digital early detection of mild cognitive impairment (MCI: ICD-10 Code F06.7). Early detection of MCI is a prerequisite for the diagnosis of Alzheimer\u2019s disease. The re.cogni.ze study shows: The neotivCare app is suitable for early detection at all levels of medical care and offers added value compared to conventional methods. The study results are of international significance and are particularly relevant for regions in which treating early-stage Alzheimer\u2019s with medication has already received regulatory approval \u2013 e.g. in the United States.<\/b><\/p>\n

<\/a>
<\/a><\/p>\n

\nThe application study re.cogni.ze is the largest study on the digital early detection of mild cognitive impairment in primary and specialized healthcare in Germany. Over a study period of 22 months, 27 neurologists and psychiatrists in private practice, 13 general practitioners (GPs) and three memory clinics, as well as 765 patients, were included in the prospective, multi-center study.<\/p>\n

\nAs part of the study, patients with subjectively perceived memory problems were prescribed the neotivCare app by their attending physician. Over a period of twelve weeks, they used the app to carry out weekly tests and self-assessments. This was done independently at home after an uncomplicated introduction to the app. At the end of the test period, the app created a letter of findings for the patients, which served as the basis for discussing the findings with their attending physician.<\/p>\n

\nHigh patient satisfaction<\/b><\/p>\n

\nAdherence among patients who activated the neotivCare app as part of the study is 93 percent. 67.6 percent report added value from the app, 51 percent state that using the app has reduced their worries.<\/p>\n

\nFULL TEXT<\/b> press release: https:\/\/mediaserver.frauwenk.de\/neotiv\/20240728_Pressemitteilung_re.cogni.ze_AAIC_EN.pdf<\/a><\/p>\n

\nAbout neotiv<\/b><\/p>\n

\nneotiv GmbH was founded in 2017 and is headquartered in Magdeburg with an additional office in Berlin. The digital health company is a spin-off of the OVGU Magdeburg in close cooperation with the German Center for Neurodegenerative Diseases (DZNE). www.neotiv.com<\/a><\/b><\/p>\n

Contacts<\/b> <\/p>\n

\nneotiv<\/b><\/p>\n

\nJ<\/b>ulian Haupenthal<\/b>
Chief Product Officer
\n
+49 175 9823543<\/p>\n

\nSilvio Riese<\/b>
Head of Commercial Operations
\n
+49 176 81113810
\n
presse@neotiv.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA–(BUSINESS WIRE)–At the Alzheimer\u2019s Association International Conference (AAIC) from July 28th to August 1st, 2024 in Philadelphia\/USA, the results of the real-world application study re.cogni.ze were presented for the first time. The study, initiated by Roche and conducted in cooperation with the digital health company neotiv, examined the user-friendliness, adherence, and acceptance of digital early … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59767","6":"format-standard","7":"category-industry"},"yoast_head":"\nre.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA–(BUSINESS WIRE)–At the Alzheimer\u2019s Association International Conference (AAIC) from July 28th to August 1st, 2024 in Philadelphia\/USA, the results of the real-world application study re.cogni.ze were presented for the first time. The study, initiated by Roche and conducted in cooperation with the digital health company neotiv, examined the user-friendliness, adherence, and acceptance of digital early ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-29T02:04:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240728520146\/en\/2198582\/22\/neotiv_LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports\",\"datePublished\":\"2024-07-29T02:04:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/\"},\"wordCount\":412,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240728520146\\\/en\\\/2198582\\\/22\\\/neotiv_LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/\",\"name\":\"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240728520146\\\/en\\\/2198582\\\/22\\\/neotiv_LOGO.jpg\",\"datePublished\":\"2024-07-29T02:04:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240728520146\\\/en\\\/2198582\\\/22\\\/neotiv_LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240728520146\\\/en\\\/2198582\\\/22\\\/neotiv_LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/","og_locale":"en_US","og_type":"article","og_title":"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports - Pharma Trend","og_description":"PHILADELPHIA–(BUSINESS WIRE)–At the Alzheimer\u2019s Association International Conference (AAIC) from July 28th to August 1st, 2024 in Philadelphia\/USA, the results of the real-world application study re.cogni.ze were presented for the first time. The study, initiated by Roche and conducted in cooperation with the digital health company neotiv, examined the user-friendliness, adherence, and acceptance of digital early ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/","og_site_name":"Pharma Trend","article_published_time":"2024-07-29T02:04:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240728520146\/en\/2198582\/22\/neotiv_LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports","datePublished":"2024-07-29T02:04:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/"},"wordCount":412,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240728520146\/en\/2198582\/22\/neotiv_LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/","url":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/","name":"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240728520146\/en\/2198582\/22\/neotiv_LOGO.jpg","datePublished":"2024-07-29T02:04:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240728520146\/en\/2198582\/22\/neotiv_LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240728520146\/en\/2198582\/22\/neotiv_LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/re-cogni-ze-study-shows-digital-early-detection-of-mild-cognitive-impairment-mci-suitable-at-all-levels-of-medical-care-neotiv-reports\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"re.cogni.ze Study Shows: Digital Early Detection of Mild Cognitive Impairment (MCI) Suitable at All Levels of Medical Care \u2013 neotiv Reports"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59767"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59767\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}